Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
McKinsey
AstraZeneca
Dow
Express Scripts

Last Updated: August 10, 2022

Bausch And Lomb Inc Company Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Bausch And Lomb Inc
International Patents:135
US Patents:8
Tradenames:13
Ingredients:11
NDAs:12
Drug Master File Entries: 1

Drugs and US Patents for Bausch And Lomb Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch And Lomb Inc LOTEMAX SM loteprednol etabonate GEL;OPHTHALMIC 208219-001 Feb 22, 2019 RX Yes Yes 10,596,107 See Plans and Pricing Y See Plans and Pricing
Bausch And Lomb Inc MACUGEN pegaptanib sodium INJECTABLE;INTRAVITREAL 021756-001 Dec 17, 2004 DISCN Yes No See Plans and Pricing See Plans and Pricing
Bausch And Lomb Inc METHAZOLAMIDE methazolamide TABLET;ORAL 207438-002 Oct 5, 2018 AB RX No No See Plans and Pricing See Plans and Pricing
Bausch And Lomb Inc XIPERE triamcinolone acetonide SUSPENSION;INJECTION 211950-001 Oct 22, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing
Bausch And Lomb Inc TIMOPTIC IN OCUDOSE timolol maleate SOLUTION/DROPS;OPHTHALMIC 019463-002 Nov 5, 1986 AT3 RX Yes Yes See Plans and Pricing See Plans and Pricing
Bausch And Lomb Inc OLOPATADINE HYDROCHLORIDE olopatadine hydrochloride SOLUTION/DROPS;OPHTHALMIC 206046-001 Jul 26, 2017 DISCN No No See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Bausch And Lomb Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bausch And Lomb Inc TIMOPTIC IN OCUDOSE timolol maleate SOLUTION/DROPS;OPHTHALMIC 019463-002 Nov 5, 1986 4,195,085 See Plans and Pricing
Bausch And Lomb Inc TIMOPTIC IN OCUDOSE timolol maleate SOLUTION/DROPS;OPHTHALMIC 019463-001 Nov 5, 1986 4,195,085 See Plans and Pricing
Bausch And Lomb Inc MACUGEN pegaptanib sodium INJECTABLE;INTRAVITREAL 021756-001 Dec 17, 2004 6,113,906 See Plans and Pricing
Bausch And Lomb Inc LOTEMAX loteprednol etabonate GEL;OPHTHALMIC 202872-001 Sep 28, 2012 5,800,807 See Plans and Pricing
Bausch And Lomb Inc TIMOPTIC IN OCUDOSE timolol maleate SOLUTION/DROPS;OPHTHALMIC 019463-002 Nov 5, 1986 3,655,663 See Plans and Pricing
Bausch And Lomb Inc MACUGEN pegaptanib sodium INJECTABLE;INTRAVITREAL 021756-001 Dec 17, 2004 5,932,462 See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for BAUSCH AND LOMB INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Ophthalmic Solution 1.5% ➤ Subscribe 2013-09-09

Supplementary Protection Certificates for Bausch And Lomb Inc Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0957929 CA 2006 00021 Denmark See Plans and Pricing PRODUCT NAME: PEGAPTANIB, NATRIUM
0957929 06C0021 France See Plans and Pricing PRODUCT NAME: PEGAPTANIB SODIUM; REGISTRATION NO/DATE: EU/1/05/325/001 20060131
0957929 SPC/GB06/021 United Kingdom See Plans and Pricing PRODUCT NAME: PEGAPTANIB, PREFERABLY IN THE FORM OF ITS SODIUM SALT; REGISTERED: UK EU/1/05/325/001 20060201
1586316 C 2011 004 Romania See Plans and Pricing PRODUCT NAME: BROMFENAC, SARURILE SI HIDRATII SAI ACCEPTABILI FARMACEUTICACID 2-[2-AMINO-3-(4-BROMOBENZOIL)FENILACETIC; NATIONAL AUTHORISATION NUMBER: RO EU/1/11/692/001; DATE OF NATIONAL AUTHORISATION: 20110518; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EMEA EU/1/11/692/001; DATE OF FIRST AUTHORISATION IN EEA: 20110518
0957929 132006901428637 Italy See Plans and Pricing PRODUCT NAME: PEGAPTANIB SODICO(MACUGEN); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/05/325/001, 20060131
1586316 2011C/027 Belgium See Plans and Pricing PRODUCT NAME: BROMFENAC; AUTHORISATION NUMBER AND DATE: EU/1/11/692/001 20110523
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
Express Scripts
Mallinckrodt
McKinsey
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.